Annovis Bio Inc. (ANVS)
NYSE: ANVS
· Real-Time Price · USD
1.99
-0.09 (-4.33%)
At close: May 23, 2025, 3:59 PM
1.98
-0.52%
After-hours: May 23, 2025, 05:24 PM EDT
Company Description
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration.
The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders.
It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia.
The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
Annovis Bio Inc.
| Country | United States |
| IPO Date | Jan 29, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Dr. Maria L. Maccecchini Ph.D. |
Contact Details
Address: 1055 Westlakes Drive Malvern, Pennsylvania United States | |
| Website | https://www.annovisbio.com |
Stock Details
| Ticker Symbol | ANVS |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001477845 |
| CUSIP Number | 03615A108 |
| ISIN Number | US03615A1088 |
| Employer ID | 26-2540421 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Maria L. Maccecchini Ph.D. | Founder, Chief Executive Officer, President & Executive Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 16, 2025 | 3 | Filing |
| May 13, 2025 | 8-K | Current Report |
| May 13, 2025 | 10-Q | Quarterly Report |
| May 12, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| May 01, 2025 | ARS | Filing |
| May 01, 2025 | DEFA14A | Filing |
| Apr 30, 2025 | DEF 14A | Filing |
| Mar 27, 2025 | 8-K | Current Report |
| Mar 21, 2025 | 10-K | Annual Report |
| Mar 21, 2025 | 8-K | Current Report |